{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:25:35Z","timestamp":1777537535504,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":1152,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013621","name":"American Society for Reconstructive Microsurgery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005616","name":"Allergan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.fertnstert.2018.12.026","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T18:19:51Z","timestamp":1552328391000},"page":"806-815.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Ulipristal acetate decreases active\u00a0TGF-\u03b23 and its canonical signaling in uterine leiomyoma via\u00a0two novel mechanisms"],"prefix":"10.1016","volume":"111","author":[{"given":"Terrence D.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1129-6575","authenticated-orcid":false,"given":"Minnie","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Britten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toral","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeris","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Catherino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2018.12.026_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0037-1599090","article-title":"Recent advances in uterine fibroid etiology","volume":"35","author":"McWilliams","year":"2017","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/ajcp\/94.4.435","article-title":"The frequency of uterine leiomyomas","volume":"94","author":"Cramer","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0950-3552(98)80059-X","article-title":"Introduction: the epidemiology of uterine leiomyomas","volume":"12","author":"Vollenhoven","year":"1998","journal-title":"Baillieres Clin Obstet Gynaecol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib4","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0029-7844(97)00534-6","article-title":"Variation in the incidence of uterine leiomyoma among premenopausal women by age and race","volume":"90","author":"Marshall","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib6","first-page":"483","article-title":"Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis","volume":"41","author":"Kjerulff","year":"1996","journal-title":"J Reprod Med"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0015-0282(02)04539-9","article-title":"The Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life","volume":"79","author":"Pron","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bpobgyn.2008.04.002","article-title":"Incidence, aetiology and epidemiology of uterine fibroids","volume":"22","author":"Okolo","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1289\/ehp.00108s5821","article-title":"Epidemiologic contributions to understanding the etiology of uterine leiomyomata","volume":"108","author":"Schwartz","year":"2000","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.rbmo.2018.04.040","article-title":"Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review","volume":"37","author":"Donnez","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5468\/ogs.2018.61.2.192","article-title":"Current medical treatment of uterine fibroids","volume":"61","author":"Sohn","year":"2018","journal-title":"Obstet Gynecol Sci"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jss.2013.07.042","article-title":"Patterns of use of hemostatic agents in patients undergoing major surgery","volume":"186","author":"Wright","year":"2014","journal-title":"J Surg Res"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib13","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/01.AOG.0000285997.38553.4b","article-title":"Hysterectomy rates in the United States, 2003","volume":"110","author":"Wu","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib14","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJM199303253281207","article-title":"Indications for hysterectomy","volume":"328","author":"Carlson","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib15","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1126\/science.1112063","article-title":"Uterine fibroids: the elephant in the room","volume":"308","author":"Walker","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.12703\/P6-113","article-title":"Recent advances in contraception","volume":"6","author":"Aiken","year":"2014","journal-title":"F1000Prime Rep"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib17","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1210\/en.2009-1225","article-title":"Progesterone is essential for maintenance and growth of uterine leiomyoma","volume":"151","author":"Ishikawa","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ki.5000054","article-title":"Renal fibrosis: new insights into the pathogenesis and therapeutics","volume":"69","author":"Liu","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib19","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","article-title":"TGF-beta-induced EMT: mechanisms and implications for\u00a0fibrotic lung disease","volume":"293","author":"Willis","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/jhep.2002.32673","article-title":"Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy","volume":"35","author":"Yata","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib21","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.175.8.5390","article-title":"TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis","volume":"175","author":"Bonniaud","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib22","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1177\/1933719109343310","article-title":"Transforming growth factor beta3 regulates the versican variants in the\u00a0extracellular matrix-rich uterine leiomyomas","volume":"16","author":"Norian","year":"2009","journal-title":"Reprod Sci"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib23","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.fertnstert.2009.01.081","article-title":"Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3","volume":"93","author":"Joseph","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib24","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0015-0282(00)00418-0","article-title":"Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation","volume":"73","author":"Arici","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-0030-1251476","article-title":"Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder","volume":"28","author":"Chegini","year":"2010","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/molehr\/gah187","article-title":"Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-beta through Smad and MAPK-mediated signalling","volume":"11","author":"Levens","year":"2005","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib27","first-page":"90","article-title":"LTBPs in biology and medicine: LTBP diseases","volume":"71","author":"Rifkin","year":"2017","journal-title":"Matrix Biol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.matbio.2015.05.005","article-title":"Latent TGF-beta-binding proteins","volume":"47","author":"Robertson","year":"2015","journal-title":"Matrix Biol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib29","first-page":"363","article-title":"Transforming growth factor-beta: a general review","volume":"7","author":"Lawrence","year":"1996","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib30","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1074\/jbc.272.10.6423","article-title":"Processing of the transforming growth factor beta type I and II receptors. Biosynthesis and ligand-induced regulation","volume":"272","author":"Koli","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib31","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1210\/jc.2002-021325","article-title":"Differential expression, regulation, and induction of Smads, transforming growth factor-beta signal transduction pathway in leiomyoma, and myometrial smooth muscle cells and alteration by gonadotropin-releasing hormone analog","volume":"88","author":"Xu","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1477-7827-1-125","article-title":"Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells","volume":"1","author":"Luo","year":"2003","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib33","doi-asserted-by":"crossref","first-page":"2414609","DOI":"10.1155\/2018\/2414609","article-title":"A comprehensive review of the pharmacologic management of uterine leiomyoma","volume":"2018","author":"Lewis","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib34","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/AOG.0b013e3181705d0e","article-title":"CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial","volume":"111","author":"Levens","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2010.09.059","article-title":"Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study","volume":"95","author":"Nieman","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib37","doi-asserted-by":"crossref","first-page":"e0173523","DOI":"10.1371\/journal.pone.0173523","article-title":"Safety after extended repeated use of ulipristal acetate for uterine fibroids","volume":"12","author":"Fauser","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib38","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1933719117728802","article-title":"Ulipristal acetate and extracellular matrix production in human leiomyomas in\u00a0vivo: a laboratory analysis of a randomized placebo controlled trial","volume":"25","author":"Cox","year":"2018","journal-title":"Reprod Sci"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib41","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.fertnstert.2015.04.025","article-title":"In\u00a0vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment","volume":"104","author":"Courtoy","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib42","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.fertnstert.2006.08.111","article-title":"Novel method to characterize primary cultures of leiomyoma and myometrium with the use of confirmatory biomarker gene arrays","volume":"87","author":"Malik","year":"2007","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib43","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.fertnstert.2008.06.030","article-title":"Activating transcription factor 3 gene expression suggests that tissue stress plays a role in leiomyoma development","volume":"92","author":"Payson","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib44","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2265.2008.03207.x","article-title":"Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells","volume":"69","author":"Malik","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib45","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021907","article-title":"Regulation of the bioavailability of TGF-beta and TGF-beta-related proteins","volume":"8","author":"Robertson","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib46","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1210\/jc.2004-0161","volume":"89","author":"Ding","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib47","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.3892\/mmr.2016.5792","article-title":"Betulinic acid and the pharmacological effects of tumor suppression (review)","volume":"14","author":"Zhang","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib48","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/med.21353","article-title":"Betulinic acid and\u00a0its\u00a0derivatives as potential antitumor agents","volume":"35","author":"Zhang","year":"2015","journal-title":"Med Res Rev"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib49","doi-asserted-by":"crossref","first-page":"936","DOI":"10.2174\/1871520614666140223192148","article-title":"Betulinic acid as a potent and complex antitumor phytochemical: a minireview","volume":"14","author":"Gheorgheosu","year":"2014","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib50","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s13277-013-0836-6","article-title":"Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study","volume":"34","author":"Eslin","year":"2013","journal-title":"Tumour Biol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib51","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/pros.22518","article-title":"Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in\u00a0vitro, and tumor growth in orthotopic mouse model for prostate cancer","volume":"72","author":"Sankpal","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2011.03.014","article-title":"Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors","volume":"122","author":"Basha","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib53","doi-asserted-by":"crossref","first-page":"e62818","DOI":"10.1371\/journal.pone.0062818","article-title":"Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors","volume":"8","author":"Otjacques","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.fertnstert.2018.12.026_bib54","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.fertnstert.2017.11.023","article-title":"Ulipristal acetate decreases transforming growth factor \u03b23 serum and tumor tissue concentrations in patients with uterine fibroids","volume":"109","author":"Ciebiera","year":"2018","journal-title":"Fertil Steril"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028219300111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028219300111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T23:48:00Z","timestamp":1765410480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028219300111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0015028219300111"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2018.12.026","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ulipristal acetate decreases active\u00a0TGF-\u03b23 and its canonical signaling in uterine leiomyoma via\u00a0two novel mechanisms","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2018.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92019 Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine","name":"copyright","label":"Copyright"}]}}